

# BC Cancer Protocol Summary for Suppressive Therapy for Pituitary Adenomas using Bromocriptine

CNB

**Protocol Code**

Neuro-Oncology

**Tumour Group**

Dr. [Rebecca Harrison](#)

**Contact Physician**

## ELIGIBILITY:

### Patients must have:

- Pituitary adenomas producing prolactin (prolactinoma) or growth hormone

## EXCLUSIONS:

- Pregnant or breast feeding women

## CAUTION:

- Uncontrolled hypertension

## TESTS:

- Baseline: Prolactin level, CT or MRI pituitary, pregnancy test if applicable, visual field and vision assessment if macroadenoma.
- At 4 weeks, repeat prolactin level, then repeated as clinically indicated
- At 6 months, prolactin level and CT pituitary; thereafter, prolactin level annually
- If clinically indicated: CT pituitary
- For macroadenoma, confirm improvement in any visual field and vision abnormalities before continuing bromocriptine on a long term basis

## PREMEDICATIONS:

- None

## TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
bromocriptine	2.5 mg bid	PO with food

## DOSE MODIFICATIONS:

### 1. Dose Titration:

- Titrate dose upward according to prolactin level
- If prolactin normalises, reduce to the lowest dose that maintains it in normal range

### 2. Visual Field Abnormalities:

- reduce dose only after visual field abnormalities have normalised and tumour shrinkage confirmed with imaging

If side effects are intolerable, may use oral tablets vaginally in female patients. A dose reduction may be required since no first pass effect with vaginal use.

## PRECAUTIONS

1. **Hypotension:** may occur during the first few days of treatment
2. **Pregnancy:** seek medical advice if pregnancy occurs during treatment.

Call Dr. **Rebecca Harrison** or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.